BIO Depositi SEC - Bio-Rad Laboratories, Inc.- Relazione annuale, dichiarazione di delega, prospetto informativo

Statistiche di base

LEI	549300ZC1GPV35XYDK53
CIK	12208

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bio-Rad Laboratories, Inc.

SEC Filings (Chronological Order)

Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.

August 26, 2025	EX-99.1	Bio-Rad Laboratories, Inc. NYSE: BIO and BIO.B August 26, 2025 Droplet Digital PCR – Powering the Future Safe Harbor Forward-Looking Statements. Some statements in this presentation and the related webinar and Q&A session may be forward-looking state dropletdigitalpcrpresent Bio-Rad Laboratories, Inc. NYSE: BIO and BIO.B August 26, 2025 Droplet Digital PCR – Powering the Future Safe Harbor Forward-Looking Statements. Some statements in this presentation and the related webinar and Q&A session may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements r
August 26, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 26, 2025 (Date of earliest event reported) BIO-RAD LABORATOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 26, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-07928 Delaware 94-1381833 (State or other jurisdiction of i
July 31, 2025	EX-99.2	1 July 31, 2025 Second Quarter 2025 Financial Results Bio-Rad Laboratories, Inc. 2 Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, includin supplementalearningspres 1 July 31, 2025 Second Quarter 2025 Financial Results Bio-Rad Laboratories, Inc.
July 31, 2025	EX-99.1	GAAP Results Q2 2025 Q2 2024 Revenue (millions) $ 651.6 $ 638.5 Gross margin 53.0 % 55.6 % Income from operations $ 77.1 $ 101.5 Net income (loss) (millions) $ 317.8 $ (2,165.5) Income (loss) per diluted share $ 11.67 $ (76.26) Non-GAAP Results Q2 20 Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2025 Financial Results HERCULES, Calif.—July 31, 2025 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2025. Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “In a hig
July 31, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 31, 2025 (Date of earliest event reported) BIO-RAD LABORATORIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 31, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-07928 Delaware 94-1381833 (State or other jurisdiction of inc
July 31, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-07928 BIO-RAD LAB
July 28, 2025	EX-99.1	Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations Exhibit 99.1 Press Release Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations HERCULES, Calif. – July 28, 2025 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective Augu
July 28, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 28, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-07928 Delaware 94-1381833 (State or other jurisdiction of inc
June 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 30, 2025 (Date of earliest event reported) BIO-RAD LABORATORIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 30, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inco
May 20, 2025	EX-1.01	Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2024 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13-p-1 to implement reporting and disclosure requirements relating to co
May 20, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELWARE 001-07928 94-1381833 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 1000 Alfred Nobel Drive, Hercules, California 94547 (Address of Principal
May 1, 2025	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 1, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or other jurisdiction of inc
May 1, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-07928 BIO-RAD LA
May 1, 2025	EX-99.1	GAAP Results Q1 2025 Q1 2024 Revenue (millions) $ 585.4 $ 610.8 Gross margin 52.3 % 53.4 % Net income (millions) $ 64.0 $ 383.9 Income per diluted share $ 2.29 $ 13.45 Non-GAAP Results Q1 2025 Q1 2024 Revenue (millions) $ 585.4 $ 610.8 Gross margin 5 Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2025 Financial Results HERCULES, Calif.—May 1, 2025 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025. Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “We navigate
April 25, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 22, 2025 (Date of earliest event reported) BIO-RAD LABORATORI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 22, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-07928 Delaware 94-1381833 (State or other jurisdiction of in
March 26, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
February 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 21, 2025 (Date of earliest event reported) BIO-RAD LABORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 21, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
February 14, 2025	EX-21.1	Listing of Subsidiaries Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium Bio-Rad Laboratórios Brasil Ltda. Brazil DiaMed Latino América S.A. Brazil Bio-Rad Laboratories (Canada) Limited Canada Bio-Rad Laboratories (Shanghai) Co., Ltd. C
February 14, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PUR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORI
February 14, 2025	EX-19.1	Insider Trading Compliance Policy Exhibit 19.1 Bio-Rad Laboratories, Inc. Insider Trading Compliance Policy Federal laws and regulations prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws and regulations also prohibit anyone who is aware of material nonpublic information from providing this information to others who may tr
February 13, 2025	8-K	Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 7, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
February 13, 2025	EX-99.1	GAAP Results Q4 2024 Q4 2023 Full-Year 2024 Full-Year 2023 Revenue (millions) $ 667.5 $ 681.2 $ 2,566.5 $ 2,671.2 Gross margin 51.2 % 53.8 % 53.7 % 53.4 % Income from operations (millions) $ 58.4 $ 95.3 $ 269.0 $ 337.8 Operating margin 8.7 % 14.0 % 1 Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results HERCULES, Calif.—February 13, 2025 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024. Norman Schwartz, Bio-Rad’s Chairman and Chief
February 13, 2025	EX-99.2	1 Exhibit 99.2 Press Release Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies Transaction To Complement Bio-Rad’s Existing Digital PCR Portfolio and Accelerate Development of Next-Generation Digital PCR Solutions HERCULES, Calif. — [BUSINESS WIRE] - February 13, 2025 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnosti
November 14, 2024	SC 13G	BIO / Bio-Rad Laboratories, Inc. / VAN ECK ASSOCIATES CORP Passive Investment SC 13G 1 bio-radlaboratoriesinc13g.htm SC 13G schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BIO-RAD LABORATORIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 090572207 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b
October 31, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-07928 BIO-RAD
October 31, 2024	EX-10.1	Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement (Non-Employee Director Form) under 2017 Incentive Award Plan Exhibit 10.1 BIO-RAD LABORATORIES, INC. 2017 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE (NON-EMPLOYEE DIRECTOR FORM) Bio-Rad Laboratories, Inc., a Delaware corporation, (the “Company”), pursuant to its 2017 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Holder”), Restricted Stock Units (“RSUs”) with respect to the
October 30, 2024	EX-99.1	GAAP Results Q3 2024 Q3 2023 Revenue (millions) $ 649.7 $ 632.1 Gross margin 54.8 % 53.1 % Operating margin 9.9 % 14.4 % Net income (millions) $ 653.2 $ 106.3 Income per diluted share $ 23.34 $ 3.64 Non-GAAP Results Q3 2024 Q3 2023 Revenue (millions) Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2024 Financial Results HERCULES, Calif.—October 30, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 p
October 30, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 30, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or other jurisdiction o
October 24, 2024	SC 13G/A	OCX / OncoCyte Corporation / BIO-RAD LABORATORIES, INC. - SC 13G/A Passive Investment SC 13G/A 1 formsc13gaoctober2024.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Oncocyte Corporation (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 68235C107 (CUSIP Number) October 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr
October 10, 2024	SC 13G/A	BIO / Bio-Rad Laboratories, Inc. / BANK OF NOVA SCOTIA - BANK OF NOVA SCOTIA Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BIO-RAD LABORATORIES (Name of Issuer) Common Shares (Title of Class of Securities) 90572207 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc
October 10, 2024	SC 13G	BIO / Bio-Rad Laboratories, Inc. / BANK OF NOVA SCOTIA - BANK OF NOVA SCOTIA Passive Investment SC 13G 1 bio101024.htm BANK OF NOVA SCOTIA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BIO-RAD LABORATORIES (Name of Issuer) Common Shares (Title of Class of Securities) 90572207 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p
September 9, 2024	EX-3.1	Amended and Restated Bylaws of Bio-Rad Laboratories, Inc. EXHIBIT 3.1 BYLAWS OF BIO-RAD LABORATORIES, INC. (as amended and restated effective September 6, 2024) OFFICES SECTION 1.Registered Office. The registered office shall be in the City of Wilmington, County of New Castle, State of Delaware. SECTION 2.Principal Office. The principal office for the transaction of the business of the corporation is hereby fixed and located at 1000 Alfred Nobel Drive, H
September 9, 2024	EX-3.2	Amended and Restated Bylaws of Bio-Rad Laboratories, Inc. effective September 6, 2024 (redline) EXHIBIT 3.2 BYLAWS OF BIO-RAD LABORATORIES, INC. (as amended and restated effective October 25, 2017September 6, 2024) OFFICES SECTION 1. Registered Office. The registered office shall be in the City of Wilmington, County of New Castle, State of Delaware. SECTION 2. Principal Office. The principal office for the transaction of the business of the corporation is hereby fixed and located at 1000 Alf
September 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 6, 2024 (Date of earliest event reported) BIO-RAD LABORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 6, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
August 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 15, 2024 (Date of earliest event reported) BIO-RAD LABORATOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 15, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of in
August 20, 2024	EX-99.1	1 Exhibit 99.1 Press Release Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer HERCULES, Calif.— August 20, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy
August 20, 2024	EX-10.1	. DiVincenzo dated August 2, 2024 Exhibit 10.1 August 2, 2024 Jon DiVincenzo 10157 Hickory Ridge Drive Zionsville, IN 46077 Dear Jon, I am pleased to extend to you our written offer of employment to join Bio-Rad Laboratories as President & Chief Operating Officer, reporting directly to Norman Schwartz. In your new position, your bi-weekly salary is $25,576.92 which is equivalent to $665,000 USD annually. You are eligible to partic
August 2, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-07928 BIO-RAD LABO
August 1, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 29, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or other jurisdiction of i
August 1, 2024	EX-99.1	GAAP Results Q2 2024 Q2 2023 Revenue (millions) $ 638.5 $ 681.1 Gross margin 55.6 % 53.2 % Operating margin 15.9 % 13.2 % Net loss (millions) $ (2,165.5) $ (1,162.3) Loss per diluted share $ (76.26) $ (39.59) Non-GAAP Results Q2 2024 Q2 2023 Revenue Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2024 Financial Results HERCULES, Calif.—August 1, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2024. Second-quarter 2024 total net sales were $638.5 million, a decrease of 6.3 percen
May 9, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-RAD LABORATORIES, INC. (Exact Name of Registrant as Specified in Charter) Commission File Number: 001-07928 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-RAD LABORATORIES, INC. (Exact Name of Registrant as Specified in Charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or Other Jurisdiction of Incorporation) (IRS Employer Identification Number) 1000 Alfred Nobel Dr. Hercules, California 94547 (Address of principal exe
May 9, 2024	EX-1.01	Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2023 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13-p-1 to implement reporting and disclosure requirements relating to co
May 8, 2024	S-8	As filed with the Securities and Exchange Commission on May 8, 2024 As filed with the Securities and Exchange Commission on May 8, 2024 Registration No.
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-07928 BIO-RAD LAB
May 8, 2024	EX-FILING FEES	Filing Fee Table. Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A Common Stock
May 7, 2024	EX-99.1	GAAP Results Q1 2024 Q1 2023 Revenue (millions) $ 610.8 $ 676.8 Gross margin 53.4 % 53.5 % Operating margin 7.3 % 9.1 % Net income (millions) $ 383.9 $ 69.0 Income per diluted share $ 13.45 $ 2.32 Non-GAAP Results Q1 2024 Q1 2023 Revenue (millions) $ Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2024 Financial Results HERCULES, Calif.—May 7, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024. First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent com
May 7, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 7, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or other jurisdiction of inc
April 26, 2024	EX-99.1	1 Exhibit 99.1 Press Release Bio-Rad Announces Life Science Group Management Changes HERCULES, Calif.— April 26, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and Pr
April 26, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 22, 2024 (Date of earliest event reported) BIO-RAD LABORATORI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 22, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or other jurisdiction of
April 26, 2024	EX-10.1	Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, as amended Exhibit 10.1 BIO-RAD LABORATORIES, INC. 2017 INCENTIVE AWARD PLAN (as amended February 9, 2024) ARTICLE 1. PURPOSE The purpose of the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan (as amended on February 9, 2024, the “Plan”) is to promote the success and enhance the value of Bio-Rad Laboratories, Inc. (the “Company”) by linking the individual interests of the members of the Board and Employ
April 22, 2024	SC 13G	OCX / OncoCyte Corporation / BIO-RAD LABORATORIES, INC. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 Oncocyte Corporation (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 68235C107 (CUSIP Number) April 15, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched
April 10, 2024	EX-99.1	1 Exhibit 99.1 Press Release Bio-Rad's Chief Operating Officer Andrew Last to Retire HERCULES, Calif.— April 10, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will
April 10, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 10, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc
March 27, 2024	DEF 14A	Notice of Annual Meeting of Stockholders Proxy Summary Proxy Statement General Information About the Meeting and Voting Item 1. Election of Directors Director Compensation Information About the Board of Directors and Corporate Governance Item 2. Rati UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
March 20, 2024	EX-99.1	Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer Exhibit 99.1 Press Release Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer HERCULES, Calif.— March 20, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju will join the company as its new Executive Vice President and Chief Financial Officer, e
March 20, 2024	EX-10.1	Employment Offer Letter between the Company and Roop K. Lakkaraju dated February 14, 2024 Exhibit 10.1 February 14, 2024 Roop Lakkaraju 1121 Grimley Lane San Jose, CA 95120 Dear Roop, I am pleased to extend to you our written offer of employment to join Bio-Rad Laboratories as Executive Vice President, Chief Financial Officer, reporting directly to Norman Schwartz. In your new position, your bi-weekly salary is $23,076.92, which is equivalent to USD $600,000 annually. You are eligible
March 20, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 20, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc
March 11, 2024	SC 13G/A	BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Bio-Rad Laboratories, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: February 29, 2024 Check the appropriate box to designate the rule pursuant to which this Sche
February 21, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 21, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
February 16, 2024	EX-97	Policy for Recovery of Erroneously Awarded Compensation, effective as of October 2, 2023 BIO-RAD LABORATORIES, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Bio-Rad Laboratories, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined in the text of this Policy are defined in Section 11. 1.Persons S
February 16, 2024	EX-21.1	Listing of Subsidiaries Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium Bio-Rad Laboratórios Brasil Ltda. Brazil DiaMed Latino-América S.A. Brazil Bio-Rad Laboratories (Canada) Limited Canada Bio-Rad Laboratories (Shanghai) Co., Ltd. C
February 16, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PUR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORI
February 15, 2024	EX-99.1	GAAP Results Q4 2023 Q4 2022 Full-Year 2023 Full-Year 2022 Revenue (millions) $ 681.2 $ 730.3 $ 2,671.3 $ 2,802.2 Gross margin 53.8 % 54.4 % 53.4 % 55.9 % Operating margin 14.0 % 16.2 % 12.6 % 17.2 % Net income (loss) (millions) $ 349.7 $ 827.7 $ (63 Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results HERCULES, Calif.—February 15, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth-quarter 2023 total net sales were $681.
February 15, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 15, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
February 14, 2024	EX-10.1	Credit Agreement, dated as of February 13, 2024, by and among Bio-Rad Laboratories, Inc., Bio-Rad Europe GmbH, Bio-Rad IHC Europe GmbH and Bio-Rad Laboratories (Singapore) Pte Ltd, the lenders referred to therein, and Wells Fargo Bank, National Association, as agent. EXHIBIT 10.1 CREDIT AGREEMENT dated as of February 13, 2024 among BIO-RAD LABORATORIES, INC., BIO-RAD EUROPE GMBH, BIO-RAD IHC EUROPE GMBH, AND BIO-RAD LABORATORIES (SINGAPORE) PTE LTD, as Borrowers, THE LENDERS, and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Agent WELLS FARGO SECURITIES, LLC, JPMORGAN CHASE BANK, N.A., and CITIBANK, N.A., as Joint Lead Arrangers and Joint Bookrunners and JPMORGAN
February 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 9, 2024 (Date of earliest event reported) BIO-RAD LABORATO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 9, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
February 13, 2024	SC 13G/A	BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0439-bioradlaboratoriesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Bio-Rad Laboratories, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropr
December 7, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 4, 2023 (Date of earliest event reported) BIO-RAD LABORATO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 4, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
October 27, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LA
October 26, 2023	EX-99.1	GAAP Results Q3 2023 Q3 2022 Revenue (millions) $ 632.1 $ 680.8 Gross margin 53.1 % 54.7 % Operating margin 14.4 % 13.9 % Net income (loss) (millions) $ 106.3 $ (162.8) Income (loss) per diluted share $ 3.64 $ (5.48) Non-GAAP Results Q3 2023 Q3 2022 Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2023 Financial Results HERCULES, Calif.—October 26, 2023 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2023. Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 perc
October 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 26, 2023 (Date of earliest event reported) BIO-RAD LABORATO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 26, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
October 17, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 12, 2023 (Date of earliest event reported) BIO-RAD LABORATO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 12, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
August 25, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 21, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of in
August 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORAT
August 4, 2023	EX-10.1	Amendment No. 4 dated as of May 12, 2023 to Credit Agreement dated as of April 15, 2019, by and among Bio-Rad Laboratories, Inc., the lenders referred to therein, and JPMorgan Chase Bank, N.A., as a lender and as administrative agen EXECUTION VERSION EXHIBIT 10.1 AMENDMENT NO. 4 Dated as of May 12, 2023 to CREDIT AGREEMENT Dated as of April 15, 2019 THIS AMENDMENT NO. 4 (this “Amendment”) is made as of May 12, 2023 by JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent’), under that certain Credit Agreement, dated as of April 15, 2019, by and among Bio-Rad Laboratories, Inc. (the “Borrower”), the Len
August 3, 2023	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 3, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc
August 3, 2023	EX-99.1	GAAP Results Q2 2023 Q2 2022 Revenue (millions) $ 681.1 $ 691.1 Gross margin 53.2 % 57.2 % Operating margin 13.2 % 17.8 % Net loss (millions) $ (1,162.3) $ (925.1) Loss per diluted share $ (39.59) $ (31.05) Non-GAAP Results Q2 2023 Q2 2022 Revenue (m Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2023 Financial Results HERCULES, Calif.—August 3, 2023 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023. Second-quarter 2023 net sales were $681.1 million, a decrease of 1.4 percent compar
July 20, 2023	EX-99.1	Bio-Rad Announces New Share Repurchase Program Exhibit 99.1 Press Release Bio-Rad Announces New Share Repurchase Program HERCULES, Calif. — July 20, 2023 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding s
July 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 20, 2023 (Date of earliest event reported) BIO-RAD LABORATORIE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 20, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inco
June 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 5, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 5, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incor
May 24, 2023	EX-1.01	Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD EX-1.01 2 ex101.htm EX-1.01 Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2022 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13-p-1 to implement reporting and disclosure
May 24, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 1000 Alfred Nobel Dr. Hercules, California 94547 (Address of principal ex
May 5, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORA
May 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 4, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 4, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incorp
May 4, 2023	EX-99.1	GAAP Results Q1 2023 Q1 2022 Revenue (millions) $ 676.8 $ 700.1 Gross margin 53.5 % 57.5 % Operating margin 9.1 % 20.9 % Net income (loss) (millions) $ 69.0 $ (3,367.3) Income (loss) per diluted share $ 2.32 $ (112.50) Non-GAAP Results Q1 2023 Q1 202 Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2023 Financial Results HERCULES, Calif.- May 4, 2023 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2023. First-quarter 2023 net sales were $676.8 million, a decrease of 3.3 percent compared t
May 1, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 25, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc
March 29, 2023	DEF 14A	Notice of Annual Meeting of Stockholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
February 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 23, 2023 (Date of earliest event reported) BIO-RAD LABORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 23, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
February 17, 2023	EX-10.13	Amendment No. 3 dated as of February 1, 2023 to Credit Agreement dated as of April 15, 2019, by and among Bio-Rad Laboratories, Inc Exhibit 10.1.3 Execution Version AMENDMENT NO. 3 Dated as of February 1, 2023 to CREDIT AGREEMENT Dated as of April 15, 2019 THIS AMENDMENT NO. 3 (this “Amendment”) is made as of February 1, 2023 by and among Bio-Rad Laboratories, Inc. (the “Borrower”), and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent’), under that certain Credit Agreement, dated as of April 15, 20
February 17, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORIES, INC
February 17, 2023	EX-21.1	Listing of Subsidiaries Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium Bio-Rad Laboratórios Brasil Ltda. Brazil DiaMed Latino-América S.A. Brazil Bio-Rad Laboratories (Canada) Limited Canada Bio-Rad Laboratories (Shanghai) Co., Ltd. C
February 16, 2023	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 16, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
February 16, 2023	EX-99.1	GAAP Results Q4 2022 Q4 2021 Revenue (millions) $ 730.3 $ 732.8 Gross margin 54.4 % 54.6 % Operating margin 16.2 % 14.9 % Net income (loss) (millions) $ 827.7 $ (1,572.2) Income (loss) per diluted share $ 27.78 $ (52.54) Non-GAAP Results Q4 2022 Q4 2 Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results HERCULES, Calif.—February 16, 2023 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022. Fourth-quarter 2022 net sales were $730.3 millio
February 9, 2023	SC 13G/A	BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Bio-Rad Laboratories Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedu
January 10, 2023	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 10, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
January 10, 2023	EX-99.1	Presentation of Bio-Rad Laboratories, Inc. dated January 10,
December 14, 2022	CORRESP	PROPOSED DISCLOSURE CORRESP 1 filename1.htm December 14, 2022 Michael Fay and Brian Cascio Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Subject: Bio-Rad Laboratories, Inc. Form 10-K for the Year Ended December 31, 2021 SEC Letters Dated April 27, 2022, and December 2, 2022 File No. 001-07928 Dear Messrs. Fay and Cascio: Bio-Rad L
November 8, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 8, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
October 28, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LA
October 28, 2022	EX-10.1	Performance Stock Unit Award Agreement under 2017 Incentive Award Plan. (2 Exhibit 10.1 BIO-RAD LABORATORIES, INC. 2017 INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT AWARD AGREEMENT Pursuant to the Performance Stock Unit Award Grant Notice (the “Grant Notice”) to which this Performance Stock Unit Award Agreement (this “Agreement”) is attached, Bio-Rad Laboratories, Inc., a Delaware corporation (the “Company”), has granted to Holder the right to receive the number of Perfor
October 27, 2022	EX-99.1	GAAP Results Q3 2022 Q3 2021 Revenue (millions) $ 680.8 $ 747.0 Gross margin 54.9 % 58.6 % Operating margin 13.6 % 21.0 % Net income (loss) (millions) $ (164.2) $ 3,928.0 Income (loss) per diluted share $ (5.52) $ 129.96 Non-GAAP Results Q3 2022 Q3 2 Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2022 Financial Results HERCULES, Calif.?October 27, 2022 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2022. Third-quarter 2022 net sales were $680.8 million, a decrease of 8.9 percent co
October 27, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 27, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
August 11, 2022	CORRESP	2 CORRESP 1 filename1.htm August 11, 2022 Michael Fay Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Subject: Bio-Rad Laboratories, Inc. Form 10-K for the Year Ended December 31, 2021 SEC Letter Dated July 29, 2022 File No. 001-07928 Dear Mr. Fay: Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) hereby subm
July 29, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORAT
July 28, 2022	EX-99.1	GAAP Results Q2 2022 Q2 2021 Revenue (millions) $ 691.1 $ 715.9 Gross margin 57.3 % 56.1 % Operating margin 17.4 % 17.4 % Net income (loss) (millions) $ (927.2) $ 914.1 Income (loss) per diluted share $ (31.12) $ 30.32 Non-GAAP Results Q2 2022 Q2 202 Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2022 Financial Results HERCULES, Calif.- July 28, 2022 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022. Second-quarter 2022 net sales were $691.1 million, a decrease of 3.5 percent compar
July 28, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 28, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inco
May 25, 2022	EX-1.01	Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. EX-1.01 2 d350596dex101.htm EX-1.01 Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2021 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13-p-1 to implement reporting and di
May 25, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 1-7928 94-1381833 (State or Other Jurisdiction of Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 1-7928 94-1381833 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 1000 Alfred Nobel Drive, Hercules, California 94547 (Address of Principal Ex
May 18, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 18, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incor
May 11, 2022	CORRESP	2 CORRESP 1 filename1.htm May 11, 2022 Michael Fay and Brian Cascio Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Subject: Bio-Rad Laboratories, Inc. Form 10-K for the Year Ended December 31, 2021 Filed February 11, 2022 File No. 001-07928 Dear Messrs. Fay and Cascio: Bio-Rad Laboratories, Inc. (“Bio-Rad” or the
April 29, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT P UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORA
April 28, 2022	EX-99.1	GAAP Results Q1 2022 Q1 2021 Revenue (millions) $ 700.1 $ 726.8 Gross margin 57.6 % 55.1 % Operating margin 20.5 % 13.9 % Net income (loss) (millions) $ (3,369.6) $ 977.4 Income (loss) per diluted share $ (112.57) $ 32.38 Non-GAAP Results Q1 2022 Q1 Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2022 Financial Results HERCULES, Calif.?April 28, 2022?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2022. First-quarter 2022 net sales were $700.1 million, a decrease of 3.7 percent compared t
April 28, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 28, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc
April 20, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 15, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc
April 20, 2022	EX-10.1	Amendment No. 2 dated as of April 15, 2022 to Credit Agreement dated as of April 15, 2019, by and among Bio-Rad Laboratories, Inc., the lenders referred to therein, and JPMorgan Chase Bank, N.A., as a lender and as administrative agent. (10) Exhibit 10.1 EXECUTION COPY AMENDMENT NO. 2 Dated as of April 15, 2022 to CREDIT AGREEMENT Dated as of April 15, 2019 THIS AMENDMENT NO. 2 (this ?Amendment?) is made as of April 15, 2022 by and among Bio-Rad Laboratories, Inc. (the ?Borrower?), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the ?Administrative Agent?), under
April 11, 2022	SC 13D/A	BIO.B / Bio-Rad Laboratories, Inc. / Schwartz Alice N - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8) Bio-Rad Laboratories, Inc. (Name of Issuer) Class B Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 090572-10-8 (CUSIP Number) Alice N. Schwartz 1000 Alfred Nobel Drive Hercules, California 94547 (510) 741-6000 (Name, Add
March 30, 2022	DEF 14A	Proxy Summary Proxy Statement General Information About the Meeting and Voting Item 1. Election of Directors Information About the Board of Directors and Corporate Governance Item 2. Ratification of Selection of Independent Auditors Report of the Aud UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.
March 28, 2022	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 23, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc
March 2, 2022	EX-4.2	First Supplemental Indenture, dated as of March 2, 2022, by and between Bio-Rad Laboratories, Inc. and Wilmington Trust, National Association. (5) Exhibit 4.2 BIO-RAD LABORATORIES, INC. as Issuer and WILMINGTON TRUST, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of March 2, 2022 to the Indenture dated as of March 2, 2022 3.300% Senior Notes due 2027 3.700% Senior Notes due 2032 TABLE OF CONTENTS Page ARTICLE 1 APPLICATION OF FIRST SUPPLEMENTAL INDENTURE Section 1.01. Application of First Supplemental Indenture 1 ARTI
March 2, 2022	EX-4.1	Indenture, dated as of March 2, 2022, by and between Bio-Rad Laboratories, Inc. and Wilmington Trust, National Association. (4) Exhibit 4.1 Bio-Rad Laboratories, Inc. INDENTURE Dated as of March 2, 2022 Wilmington Trust, National Association Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section
March 2, 2022	EX-4.3	Form of Global Security for the 3.300% Senior Notes due 2027. (6) Exhibit 4.3 BIO-RAD LABORATORIES, INC. THIS GLOBAL NOTE IS HELD BY THE DEPOSITARY (AS DEFINED IN THE FIRST SUPPLEMENTAL INDENTURE GOVERNING THIS NOTE) OR ITS NOMINEE IN CUSTODY FOR THE BENEFIT OF THE BENEFICIAL OWNERS HEREOF, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT THAT (I) THE TRUSTEE MAY MAKE SUCH NOTATIONS HEREON AS MAY BE REQUIRED PURSUANT TO SECTION 3.02 OF THE FI
March 2, 2022	EX-1.1	Underwriting Agreement, dated as of February 23, by and among Bio-Rad Laboratories, Inc. and Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, and J.P. Morgan Securities LLC as representatives of the several underwriters named in Schedule A thereto. Exhibit 1.1 Bio-Rad Laboratories, Inc. $400,000,000 3.300% Senior Notes due 2027 $800,000,000 3.700% Senior Notes due 2032 UNDERWRITING AGREEMENT February 23, 2022 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 As Representatives of th
March 2, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 23, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact Name of Registrant as Specified in its Charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
March 2, 2022	EX-99.1	Announces Closing of $1.2 Billion Aggregate Senior Notes Offering Exhibit 99.1 Bio-Rad Announces Closing of $1.2 Billion Aggregate Senior Notes Offering HERCULES, California?March 2, 2022?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today the closing of its underwritten public offering of $1.2 billion aggregate principal amount of the following notes (the ?Notes?), each issu
March 2, 2022	EX-4.4	Form of Global Security for the 3.700% Senior Notes due 2032. (7) Exhibit 4.4 BIO-RAD LABORATORIES, INC. THIS GLOBAL NOTE IS HELD BY THE DEPOSITARY (AS DEFINED IN THE FIRST SUPPLEMENTAL INDENTURE GOVERNING THIS NOTE) OR ITS NOMINEE IN CUSTODY FOR THE BENEFIT OF THE BENEFICIAL OWNERS HEREOF, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT THAT (I) THE TRUSTEE MAY MAKE SUCH NOTATIONS HEREON AS MAY BE REQUIRED PURSUANT TO SECTION 3.02 OF THE FI
February 25, 2022	EX-99.1	F E B R U A R Y 2 5 , 2 0 2 2 Exhibit 99.1 F E B R U A R Y 2 5 , 2 0 2 2 Bio-Rad Investor Laboratories, Inc. Day 2022 Forward-Looking Statements & Use of Non-GAAP Reporting Forward-looking Statements. Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management?s goals, plans, and
February 25, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 25, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
February 25, 2022	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) BIO-RAD LABORATORIES, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) BIO-RAD LABORATORIES, INC.
February 25, 2022	EX-99.2	Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor Day Exhibit 99.2 Press Release Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor Day HERCULES, Calif.?February 25, 2022? Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, is hosting an in-person investor day beginning at 10:30 a.m. EST today in New York City. During the event, members of Bio-Rad?
February 25, 2022	424B2	$1,200,000,000 $400,000,000 3.300% Senior Notes due 2027 $800,000,000 3.700% Senior Notes due 2032 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-262737 PROSPECTUS SUPPLEMENT (To Prospectus dated February 15, 2022) $1,200,000,000 $400,000,000 3.300% Senior Notes due 2027 $800,000,000 3.700% Senior Notes due 2032 We are offering $400,000,000 aggregate principal amount of our 3.300% Senior Notes due 2027 (the ?2027 notes?), and $800,000,000 aggregate principal amount of o
February 24, 2022	FWP	Bio-Rad Laboratories, Inc. Pricing Term Sheet February 23, 2022 $400,000,000 3.300% Senior Notes due 2027 $800,000,000 3.700% Senior Notes due 2032 Issuer: Bio-Rad Laboratories, Inc. (the “Company”) Trade Date: February 23, 2022 Settlement Date*: Mar FWP 1 d84576dfwp.htm FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-262737 Relating to the Preliminary Prospectus Supplement dated February 23, 2022 Bio-Rad Laboratories, Inc. Pricing Term Sheet February 23, 2022 $400,000,000 3.300% Senior Notes due 2027 $800,000,000 3.700% Senior Notes due 2032 Issuer: Bio-Rad Laboratories, Inc. (the “Company”) Trade Date: Febr
February 23, 2022	424B5	SUBJECT TO COMPLETION, DATED FEBRUARY 23, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-262737 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933. This preliminary prospec
February 15, 2022	EX-25.1	Statement of Eligibility of trustee under the Indenture. Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) WILMINGTON TRUST, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) 16-1486454 (I.R.S. employer identification no.) 1100 North Market Street Wilmington, DE 19890-0001 (Address of principal
February 15, 2022	S-3ASR	As filed with the Securities and Exchange Commission on February 15, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 15, 2022 Registration No.
February 15, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BIO-RAD LABORATORIES, INC.
February 15, 2022	EX-4.2	Form of Indenture Exhibit 4.2 Bio-Rad Laboratories, Inc. INDENTURE Dated as of , Wilmington Trust, National Association Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 5 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuabl
February 11, 2022	EX-10.9	Executive Change in Control Severance Plan Adopted 2-10-2022 EXHIBIT 10.9 BIO-RAD LABORATORIES, INC. EXECUTIVE CHANGE IN CONTROL SEVERANCE PLAN The purpose of the Bio-Rad Laboratories, Inc. Executive Change in Control Severance Plan (as amended and in effect from time to time, the ?Plan?), is to provide key executives with certain severance benefits upon their termination of employment following a Change in Control. The Compensation Commit
February 11, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORIES, INC
February 11, 2022	EX-21.1	Listing of Subsidiaries. Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria DiaMed ?sterreich GmbH Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium DiaMed Benelux NV Belgium Bio-Rad Laborat?rios Brasil Ltda. Brazil DiaMed Latino-Am?rica S.A. Brazil Bio-Rad Laboratories (Rishon),
February 10, 2022	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 10, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
February 10, 2022	EX-99.1	GAAP Results Q4 2021 Q4 2020 Revenue (millions) $ 732.8 $ 789.8 Gross margin 54.7 % 58.3 % Operating margin 14.6 % 22.2 % Net (loss) income (millions) $ (1,573.7) $ 839.1 (Loss) income per diluted share $ (52.59) $ 27.81 Non-GAAP Results Q4 2021 Q4 2 Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2021 Financial Results HERCULES, Calif.?February 10, 2022?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and year ended December 31, 2021. Fourth-quarter 2021 net sales were $732.8 million, a de
February 9, 2022	SC 13G/A	BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Bio-Rad Laboratories Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedu
November 29, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 21, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
November 18, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 15, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
November 18, 2021	EX-10.1	Amendment No. 1 dated as of November 15, 2021 to Credit Agreement dated as of April 15, 2019, by and among Bio-Rad Laboratories, Inc., the lenders referred to therein, and JPMorgan Chase Bank, N.A., as a lender and as administrative agent. Exhibit 10.1 EXECUTION COPY AMENDMENT NO. 1 Dated as of November 15, 2021 to CREDIT AGREEMENT Dated as of April 15, 2019 THIS AMENDMENT NO. 1 (this ?Amendment?) is made as of November 15, 2021 by and among Bio-Rad Laboratories, Inc. (the ?Borrower?), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the ?Administrative Agent?),
October 29, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LA
October 28, 2021	EX-99.1	GAAP Results Q3 2021 Q3 2020 Revenue (millions) $ 747.0 $ 647.3 Gross margin 58.6 % 56.7 % Operating margin 21.0 % 16.9 % Net income (millions) $ 3,928.0 $ 1,314.8 Income per diluted share $ 129.96 $ 43.64 Non-GAAP Results Q3 2021 Q3 2020 Revenue (mi Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2021 Financial Results HERCULES, Calif.?October 28, 2021?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2021. Third-quarter 2021 net sales were $747.0 million, an increase of 15.4 percent co
October 28, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 28, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
October 4, 2021	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 28, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
July 30, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ☐ TRANSITION REPORT PU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORAT
July 29, 2021	EX-99.1	GAAP Results Q2 2021 Q2 2020 Revenue (millions) $ 715.9 $ 536.9 Gross margin 56.1 % 54.6 % Operating margin 17.4 % 9.6 % Net income (millions) $ 914.1 $ 966.4 Income per diluted share $ 30.32 $ 32.15 Non-GAAP Results Q2 2021 Q2 2020 Gross margin 56.9 Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2021 Financial Results HERCULES, Calif.?July 29, 2021?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2021. Second-quarter 2021 net sales were $715.9 million, an increase of 33.4 percent compare
July 29, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 29, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inco
May 17, 2021	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 1-7928 94-1381833 (State or Other Jurisdiction of Inc UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 1-7928 94-1381833 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 1000 Alfred Nobel Drive, Hercules, California 94547 (Address of Principal Ex
May 17, 2021	EX-1.01	Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (?Bio-Rad? or the ?Company?) is for calendar year 2020 in accordance with Rule 13p-1 (?Rule 13p-1?) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (?SEC?) adopted Rule 13-p-1 to implement reporting and disclosure requirements relating to co
April 30, 2021	10-Q	Quarterly Report - 10-Q MARCH 31, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORA
April 29, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 29, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc
April 29, 2021	EX-99.1	GAAP Results Q1 2021 Q1 2020 Revenue (millions) $ 726.8 $ 571.6 Gross margin 55.1 % 55.5 % Operating margin 13.9 % 13.0 % Net income (millions) $ 977.4 $ 685.9 Income per diluted share $ 32.38 $ 22.72 Non-GAAP Results Q1 2021 Q1 2020 Gross margin 59. Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2021 Financial Results HERCULES, Calif.?April 29, 2021?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2021. First-quarter 2021 net sales were $726.8 million, an increase of 27.1 percent compared
March 31, 2021	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Prox
February 16, 2021	EX-21.1	Listing of Subsidiaries. Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria DiaMed ?sterreich GmbH Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium DiaMed Benelux NV Belgium Bio-Rad Laborat?rios Brasil Ltda. Brazil DiaMed Latino-Am?rica S.A. Brazil Bio-Rad Laboratories (Rishon),
February 16, 2021	10-K	Annual Report - 10-K 12.31.20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORIES, INC
February 11, 2021	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 11, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
February 11, 2021	EX-99.1	GAAP Results Q4 2020 Q4 2019 Revenue (millions) $ 789.8 $ 624.4 Gross margin 58.3 % 52.9 % Operating margin 22.2 % 9.5 % Net income (millions) $ 839.1 $ 553.5 Income per diluted share $ 27.81 $ 18.31 Non-GAAP Results Q4 2020 Q4 2019 Revenue (millions Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2020 Financial Results HERCULES, Calif.–February 11, 2021–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter ended December 31, 2020. Fourth-quarter 2020 net sales were $789.8 million, an increase o
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Bio-Rad Laboratories Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedu
February 4, 2021	8-K	Costs Associated with Exit or Disposal Activities - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 3, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
January 5, 2021	CORRESP	- Bio-Rad Laboratories, Inc. Corporate Offices 1000 Alfred Nobel Drive Hercules, California 94547 Phone: 510-724-7000 Fax: 510-741-4048 January 5, 2021 Jeanne Bennett Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Subject: Bio-Rad Laboratories, Inc. Form 10-K for the Year Ended December 31, 2019 Filed March 2, 202
December 10, 2020	EX-99.2	Provides Outlook Through 2023 Exhibit 99.2 Press Release Bio-Rad Provides Outlook Through 2023 HERCULES, Calif ?December 10, 2020?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today its outlook through 2023, which shows the company?s commitment to continued organic growth, continued margin expansion, and its efforts on sustainability measur
December 10, 2020	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 10, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
December 10, 2020	EX-99.1	FORWARD-LOOKING STATEMENTS & USE OF NON-GAAP REPORTING Forward-looking Statements. Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without l Exhibit 99.1 OUTLOOK: 2021 ? 2023 Bio-Rad Laboratories, Inc. December 10, 2020 ? 2020 Bio-Rad Laboratories, Inc. All rights reserved.Exhibit 99.1 OUTLOOK: 2021 ? 2023 Bio-Rad Laboratories, Inc. December 10, 2020 ? 2020 Bio-Rad Laboratories, Inc. All rights reserved. FORWARD-LOOKING STATEMENTS & USE OF NON-GAAP REPORTING Forward-looking Statements. Some statements in this presentation may be forwar
October 30, 2020	10-Q	Quarterly Report - 10-Q SEPTEMBER 30, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LA
October 30, 2020	EX-10.2	Stock Option Grant Notice and Non-Qualified Stock Option Agreement under 2017 Incentive Award Plan (updated September 2020) BIO-RAD LABORATORIES, INC. 2017 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE AND NON-QUALIFIED STOCK OPTION AGREEMENT (United States HOLDERS) Bio-Rad Laboratories, Inc., a Delaware corporation (the “Company”), pursuant to its 2017 Incentive Award Plan (the “Plan”), hereby grants to the holder listed below (“Holder”), an option to purchase the number of shares of the Company’s Class A common stoc
October 30, 2020	EX-10.1	Global Restricted Stock Unit Award Grant Notice and Global Restricted Stock Unit Award Agreement under 2017 Incentive Award Plan (updated September 2020) BIO-RAD LABORATORIES, INC. 2017 INCENTIVE AWARD PLAN GLOBAL RESTRICTED STOCK Unit AWARD GRANT NOTICE Bio-Rad Laboratories, Inc., a Delaware corporation, (the “Company”), pursuant to its 2017 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Holder”), Restricted Stock Units (“RSUs”) with respect to the number of shares of the Company’s C
October 29, 2020	EX-99.1	GAAP Results Q3 2020 Q3 2019 Revenue (millions) $ 647.3 $ 560.6 Gross margin 56.7 % 54.8 % Operating margin 16.9 % 10.2 % Net income (loss) (millions) $ 1,314.8 $ (258.8) Income (loss) per diluted share $ 43.64 $ (8.68) Non-GAAP Results Q3 2020 Q3 20 Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2020 Financial Results HERCULES, Calif.–October 29, 2020–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2020. Third-quarter 2020 net sales were $647.3 million, an increase of 15.5 percent co
October 29, 2020	8-K	Results of Operations and Financial Condition - 8-K 10.29.20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 29, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
September 4, 2020	EX-24	EX-24 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Ronald W.
July 31, 2020	10-Q	Quarterly Report - 10-Q JUNE 30, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORAT
July 30, 2020	EX-99.1	GAAP Results Q2 2020 Q2 2019 Revenue (millions) $ 536.9 $ 572.6 Gross margin 54.6 % 53.7 % Operating margin 9.6 % 9.8 % Net income (millions) $ 966.4 $ 598.8 Income per diluted share $ 32.15 $ 19.86 Non-GAAP Results Q2 2020 Q2 2019 Gross margin 55.5 Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2020 Financial Results HERCULES, Calif.–July 30, 2020–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2020. Second-quarter 2020 net sales were $536.9 million, a decrease of 6.2 percent compared
July 30, 2020	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 30, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inco
May 28, 2020	EX-1.01	Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2019 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13-p-1 to implement reporting and disclosure requirements relating to co
May 28, 2020	SD	- SD 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 1-7928 94-1381833 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 1000 Alfred Nobel Drive, Hercules, California 94547 (Address of Principal Ex
May 21, 2020	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 21, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incor
May 8, 2020	10-Q	Quarterly Report - 10-Q MARCH 31, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORA
May 6, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 6, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incorp
May 6, 2020	EX-99.1	GAAP Results Q1 2020 Q1 2019 Revenue (millions) $ 571.6 $ 554.0 Gross margin 55.5 % 56.3 % Operating margin 13.0 % 10.2 % Net income (millions) $ 685.9 $ 865.2 Income per diluted share $ 22.72 $ 28.74 Non-GAAP Results Q1 2020 Q1 2019 Gross margin 55. Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2020 Financial Results HERCULES, Calif.-May 6, 2020-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2020. First-quarter 2020 net sales were $571.6 million, an increase of 3.2 percent compared to
May 1, 2020	8-K	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 28, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc
April 6, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 1, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inco
April 1, 2020	DEF 14A	BIO / Bio-Rad Laboratories, Inc. DEF 14A - - BIO RAD LABORATORIES INC - DEF 14A BIO-RAD LABORATORIES, INC. - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted
March 2, 2020	10-K	Annual Report - 10-K 12.31.19 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORIES, INC
March 2, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 25, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
March 2, 2020	EX-21.1	Listing of Subsidiaries. Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria DiaMed Österreich GmbH Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium DiaMed Benelux NV Belgium Bio-Rad Laboratórios Brasil Ltda. Brazil DiaMed Latino-América S.A. Brazil Bio-Rad Laboratories (Rishon),
March 2, 2020	EX-4.1	Description of Bio-Rad Laboratories, Inc. Class A and Class B Common Stock Exhibit 4.1 DESCRIPTION OF BIO-RAD LABORATORIES, INC. CLASS A AND CLASS B COMMON STOCK The following description of Bio-Rad Laboratories, Inc.’s (“Bio-Rad’s”) Class A Common Stock and Class B Common Stock is a summary. This summary is subject to the General Corporation Law of the State of Delaware (the “DGCL”), the complete text of Bio-Rad’s Restated Certificate of Incorporation and Certificate of
February 13, 2020	EX-99.1	GAAP Results Q4 2019 Q4 2018 Revenue (millions) $ 624.4 $ 616.8 Gross margin 52.9 % 53.9 % Operating margin 9.5 % (36.8 )% Net income (loss) (millions) $ 553.5 $ (828.5 ) Income (loss) per diluted share $ 18.31 $ (27.73 ) Non-GAAP Results Q4 2019 Q4 Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results HERCULES, Calif.- February 13, 2020-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2019. Fourth-quarter 2019 net sales were $624.4 million
February 13, 2020	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 13, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
February 12, 2020	SC 13G/A	BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Bio-Rad Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is fil
December 9, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 5, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
November 25, 2019	8-K	Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 21, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
November 1, 2019	10-Q	Quarterly Report - 10-Q SEPTEMBER 30, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LA
October 31, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 31, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
October 31, 2019	EX-99.1	GAAP Results Q3 2019 Q3 2018 Revenue (Millions) $ 560.6 $ 545.1 Gross Margin 54.8 % 52.6 % Operating Margin 10.2 % 6.7 % Net (Loss) Income (Millions) $ (258.8 ) $ 269.3 (Loss) Income per Diluted Share $ (8.68 ) $ 8.89 Non-GAAP Results Q3 2019 Q3 2018 Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2019 Financial Results HERCULES, Calif.-October 31, 2019-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2019. Third-quarter 2019 net sales were $560.6 million, an increase of 2.8 percent com
August 27, 2019	EX-99.1	GAAP Results EX-99.1 Exhibit 99.1 Corrected Press Release Bio-Rad Reports Second-Quarter 2019 Financial Results HERCULES, Calif.–August 27, 2019– This press release corrects a prior version published on August 1, 2019. The prior press release contained a $3.37 million error with respect to Legal Matters used in the non-GAAP financial presentation. This corrected press release does not change the GAAP results o
August 27, 2019	8-K/A	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 1, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other
August 23, 2019	EX-10.1	Retirement Agreement between the Company and John Hertia made as of August 21, 2019 EX-10.1 Exhibit 10.1 Retirement Agreement THIS RETIREMENT AGREEMENT (the “Agreement”) is made as of this 21st day of August 2019, by and between BIO-RAD LABORATORIES, INC. (“Company”) and John Hertia (“Executive”) (individually, a “PARTY”, and collectively, the “PARTIES”). It shall outline the agreed upon terms for Executive’s retirement from company as follows: 1. Retirement Date. The parties agr
August 23, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 20, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of in
August 6, 2019	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORAT
August 1, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 1, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc
August 1, 2019	EX-99.1	GAAP Results Q2 2019 Q2 2018 Revenue (Millions) $572.6 $575.9 Gross Margin 53.7% 52.4% Operating Margin 9.8% 7.6% Net Income (Millions) $598.8 $268.0 Income per Diluted Share $19.86 $8.87 Non-GAAP Results Q2 2019 Q2 2018 Gross Margin 54.4% 53.4% Oper Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2019 Financial Results HERCULES, Calif.-August 1, 2019-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2019. Second-quarter 2019 net sales were $572.6 million, a decrease of 0.6 percent compared
July 12, 2019	SC 13D/A	BIO / Bio-Rad Laboratories, Inc. / Schwartz Alice N - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7) Bio-Rad Laboratories, Inc. (Name of Issuer) Class B Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 090572-10-8 (CUSIP Number) Alice N. Schwartz 1000 Alfred Nobel Drive Hercules, California 94547 (510) 741-6000 (Name, Add
May 10, 2019	10-Q	Quarterly Report - 10-Q MARCH 31, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORA
May 8, 2019	EX-99.1	GAAP Results Exhibit 99.1 Press Release Bio-Rad Reports First Quarter 2019 Financial Results HERCULES, Calif.-May 8, 2019-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2019. First-quarter 2019 net sales were $554.0 million, an increase of 0.4 percent compared to
May 8, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 8, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incorp
May 3, 2019	EX-1.01	EXHIBIT 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of the Form SD Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2018 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13-p-1 to implement reporting and disclosure requirements relating to co
May 3, 2019	SD	BIO / Bio-Rad Laboratories, Inc. SD SD 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 1-7928 94-1381833 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 1000 Alfred Nobel Drive, Hercules, California 94547 (Address of Principal Ex
May 2, 2019	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 . FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 .. Date of Report: April 29, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 . Delaware 94-1381833 (State or other jurisdiction
April 22, 2019	EX-10.1	Employment Offer Letter between the Company and Andrew J. Last dated March 15, 2019 (1 EX-10.1 Exhibit 10.1 Bio-Rad Laboratories, Inc. Corporate Offices 1000 Alfred Nobel Drive Hercules, California 94547 Phone: 510-724-7000 Fax: 510-741-5865 March 15, 2019 Andrew J. Last 3 Shadewell Court Danville, CA 94506 Dear Andrew, I am pleased to extend to you our written offer of employment to join Bio-Rad Laboratories as the Chief Operating Officer reporting directly to Norman Schwartz, Pres
April 22, 2019	8-K	Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 22, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
April 22, 2019	EX-99.1	Appoints Andrew Last as Executive Vice President and Chief Operating Officer EX-99.1 Exhibit 99.1 Press Release Bio-Rad Appoints Andrew Last as Executive Vice President and Chief Operating Officer HERCULES, Calif.–April 22, 2019–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the appointment of Dr. Andrew Last as Executive Vice President and Chief Operating Officer, effective April
April 16, 2019	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Termination of a Material Definitive Agreement 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 15, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
April 16, 2019	EX-10.1	Credit Agreement, dated as of April 15, 2019, by and among Bio-Rad Laboratories, Inc., the lenders referred to therein, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A., HSBC Bank USA National Association, and EX-10.1 Exhibit 10.1 EXECUTION VERSION CREDIT AGREEMENT dated as of April 15, 2019 among BIO-RAD LABORATORIES, INC., THE LENDERS, JPMORGAN CHASE BANK, N.A., as Administrative Agent, BANK OF AMERICA, N.A., HSBC BANK USA, NATIONAL ASSOCIATION, and MUFG UNION BANK, N.A., as Co-Syndication Agents, and CITIBANK, N.A. and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Co-Documentation Agents, JPMORGAN CHASE
April 4, 2019	DEF 14A	BIO / Bio-Rad Laboratories, Inc. BIO RAD LABORATORIES INC - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Prox
April 2, 2019	EX-99.1	Names Ilan Daskal Executive Vice President and Chief Financial Officer EX-99.1 Exhibit 99.1 Press Release Bio-Rad Names Ilan Daskal Executive Vice President and Chief Financial Officer HERCULES, California. — April 2, 2019 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that the appointment of Ilan Daskal as Executive Vice President and Chief Financial Officer, effective Apr
April 2, 2019	EX-10.1	Employment Offer Letter between the Company and Ilan Daskal dated March 15, 2019 (1 EX-10.1 Exhibit 10.1 March 15, 2019 llan Daskal 1731 Juarez Avenue Los Altos, CA 94024 Dear llan, I am pleased to extend to you our written offer of employment to join Bio-Rad Laboratories as the EVP & Chief Financial Officer reporting directly to Norman Schwartz, President & CEO. In your new position, your bi-weekly salary will be $19,230.77, equivalent to $500,000 annually. You are eligible to p
April 2, 2019	8-K	Financial Statements and Exhibits 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 2, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
April 1, 2019	10-K	Annual Report - 10-K 12.31.18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORIES, INC
April 1, 2019	EX-21.1	Listing of Subsidiaries. Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria DiaMed Österreich GmbH Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium DiaMed Benelux NV Belgium Bio-Rad Laboratórios Brasil Ltda. Brazil DiaMed Latino-América S.A. Brazil Bio-Metrics Properties Limited
March 25, 2019	EX-99.1	Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form EX-99.1 Exhibit 99.1 Press Release Bio-Rad Laboratories, Inc. Receives Expected NYSE Notice Regarding Late Form 10-K Filing HERCULES, California. - March 25, 2019 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it had received an expected notice from the New York Stock Exchange (the “NYSE”) stating t
March 25, 2019	8-K	Financial Statements and Exhibits 8-K 1 d640166d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2019 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 1-7928 94-1381833 (State or other jurisdiction of in
March 18, 2019	8-K	Current Report 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 18, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 1-7928 94-1381833 (State or other jurisdiction of incorporation or organi
March 4, 2019	NT 10-K	BIO / Bio-Rad Laboratories, Inc. NT 10-K NT 10-K SEC FILE NUMBER 001-07928 CUSIP NUMBER 090572207 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 28, 2019	8-K	Current Report 8-K 1 bio-8k2282019.htm 8-K FEBRUARY 28, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 28, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delawa
February 28, 2019	EX-99.1	GAAP Results Q4 2018 Q4 2017 Revenue (Millions) $617.5 $621.3 Gross Margin 54.0% 55.6% Operating Margin (37.6%) 9.0% Net (Loss) Income (Millions) ($833.1) $82.7 (Loss) Income per Diluted Share ($27.88) $2.75 Non-GAAP Results Q4 2018 Q4 2017 Gross Mar Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2018 Financial Results HERCULES, Calif.-February 28, 2019-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2018. Fourth-quarter 2018 net sales were $617.5 million,
February 15, 2019	SC 13G/A	BIO / Bio-Rad Laboratories, Inc. / EATON VANCE MANAGEMENT - BIORAD Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* (Name of Issuer) BIO RAD LABORATORIES INC COMMON STOCK (Title of Class of Securities) 090572207 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t
February 11, 2019	SC 13G/A	BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC Passive Investment bioradlaboratoriesinc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4 )* Name of issuer: Bio-Rad Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: December 31, 2018 Check the appro
January 3, 2019	8-K	Current Report 8-K 1 d684144d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2019 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-79
January 3, 2019	EX-99.1	Christine Tsingos Announces Plans to Retire as CFO of EX-99.1 Exhibit 99.1 Christine Tsingos Announces Plans to Retire as CFO of Bio-Rad Laboratories, Inc. Effective April 30, 2019 HERCULES, Calif.–January 3, 2019–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Christine A. Tsingos has informed the company of her intention to retire as Executive Vice Pres
December 4, 2018	8-K	Other Events, Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2018 BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Delaware 1-7928 94-1381833 (State or other jurisdiction of incorporation) (Commissio
November 5, 2018	10-Q	Quarterly Report - 10-Q SEPTEMBER 30, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LA
November 1, 2018	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 1, 2018 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i
November 1, 2018	EX-99.1	GAAP Results Q3 2018 Q3 2017 Revenue (Millions) $545.1 $534.1 Gross Margin 52.6% 56.0% Operating Margin 6.7% 7.3% Net Income (Millions) $269.3 $22.1 Income per Diluted Share $8.89 $0.73 Non-GAAP Results Q3 2018 Q3 2017 Gross Margin 53.5% 56.9% Operat Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2018 Financial Results HERCULES, Calif.-November 1, 2018-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2018. Third-quarter 2018 net sales were $545.1 million, an increase of 2.1 percent com
August 9, 2018	10-Q	Quarterly Report - 10-Q JUNE 30, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORAT
August 7, 2018	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 7, 2018 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc
August 7, 2018	EX-99.1	GAAP Results Q2 2018 Q2 2017 Revenue (Millions) $575.9 $504.7 Gross Margin 52.4% 54.2% Operating Margin 7.6% (0.3)% Net Income (Millions) $268.0 $5.0 Income per Diluted Share $8.87 $0.17 Non-GAAP Results Q2 2018 Q2 2017 Gross Margin 53.4% 55.6% Opera Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2018 Financial Results HERCULES, Calif.-August 7, 2018-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2018. Second-quarter 2018 net sales were $575.9 million, an increase of 14.1 percent compar
June 18, 2018	8-K	Current Report 8-K 1 a8k6182018.htm 8-K JUNE 18, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 14, 2018 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-13818
May 10, 2018	10-Q	Quarterly Report - 10-Q MARCH 31, 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORA
May 8, 2018	EX-99.1	GAAP Results Exhibit 99.1 Press Release Bio-Rad Reports First Quarter 2018 Financial Results HERCULES, Calif.-May 8, 2018-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2018. First-quarter 2018 net sales were $551.5 million, an increase of 10.3 percent compared to
May 8, 2018	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 8, 2018 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incorp
May 4, 2018	EX-1.01	Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2017 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13-p-1 to implement reporting and disclosure requirements relating to co
May 4, 2018	SD	BIO / Bio-Rad Laboratories, Inc. SD 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 1-7928 94-1381833 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 1000 Alfred Nobel Drive, Hercules, California 94547 (Address of Principal Ex
May 4, 2018	DEF 14A	BIO / Bio-Rad Laboratories, Inc. BIO RAD LABORATORIES INC - DEF 14A BIO-RAD LABORATORIES, INC. - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted
April 26, 2018	10-K/A	Annual Report - 10-K/A 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 18, 2018	8-K	Current Report 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 18, 2018 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of
April 16, 2018	10-K	Annual Report - 10-K 2017 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2017 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORIES, INC

BIO / Bio-Rad Laboratories, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

Statistiche di base

SEC Filings

SEC Filings (Chronological Order)

Other Listings